Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...

Tonix Pharma (TNXP) has submitted an NDA for its candidate TNX-102 SL for fibromyalgia, with a PDUFA date set for August 15, 2025. See why I'm on the sidelines.

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Novo Nordisk has acquired the global rights to United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal ...

Obesity remains a significant public health challenge in the UK, with over 26% of adults classified as obese and an additional 38% considered overweight. This epidemic not only impacts individual ...

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Cibc World Markets Corp bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the fourth quarter, ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...